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conscious rat. Am. J. Physiol. 251 (Heart Circ. Physiol. 20): 
H700-H709, 1986.-The effect of leukotrienes (L Ts) D4 and 
E4 on systemic and regional hemodynamic variables were stud-
ied in the conscious rat (n =5-9). Renal (R) , mesenteric (M), 
and hindquarter (HQ) blood flow (BF) were monitored by 
directional pulsed Doppler velocimetry, and mean arterial blood 
pressure (MAP) and heart rate were recorded through a cath-
eter in the femoral artery. In a separate series of experiments, 
cardiac index (CI) was measured by the thermodilution method. 
Systemic injection of LTD4 or LTE4 (0.1-10 ~g/kg) produced 
dose-dependent pressor responses; BF in the M, HQ, and R 
vessels declined, due to increased vascular resistance (VR) at 
the following order: M >> HQ > R. Low doses of L TD4 or L TE4 
produced vasodilation in the HQ area. Infusion ofLTD4 (3 /J.g· 
kg-1 ·min-1) for 10 min produced progressive and pronounced 
vascular constriction in the M and H Q regions along with 
reduction in BF. The LTD4 infusionalso markedly decreased 
CI with a concomitant rise in total peripheral resistance index 
(TPRI). Indomethacin (5 mg/kg iv) pretreatment did not mod-
ify any of the hemodynamic effects of LTD4 or LTE4. FPL 
55712 (10 mg/kg iv) and L Y 171883 (30 mg/kg iv), two different 
LT -receptor antagonists, partially blocked the constriction ef-
fects of these LTs. LY 171883, but not FPL 55172, blocked the 
H Q vasodilation produced by L TE ... L Y 171883 alone increased 
HQ-BF and reduced HQ-VR. These data indicate that LTD4 
and L TE4 are potent constrictors of the M vascular bed, but at 
low doses they also produce dilation of the HQ blood vessels. 
Furthermore, no escape from the effects of prolonged infusion 
of the L Ts was demonstrated in this species. Finally, the 
hemodynamic responses to L TD4 and LTE4 in the conscious 
rat are independent of cyclooxygenase products of L Ts and are 
only partially blocked by FPL 55712 or L Y 171883. These 
studies taken together suggest a differential distribution of 
multiple L T receptors in the rat vasculature. 
indomethacin; blood pressure; renal blood flow; mesenteric 
blood flow; leukotriene antagonists; anaphylactic shock 
THE PEPTIDOLEUKOTRIENES (LTs) are 5-lipoxygenase 
metabolites of arachidonic acid, which have been shown 
to be the active constituents of the slow reacting sub-
stance of anaphylaxis (SRS-A) (27). The potent vasoac-
tive properties of the LTs are well established, but major 
differences occur between various in vitro vs. in vivo 
preparations and among diverse species (9). Although 
most normal vascular preparations constrict in response 
to in vitro LTs (for review see Ref. 9), some reports show 
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the opposite (14, 18, 19). In most species studied, in vivo 
L Ts produce a pressor response, but hypotension is the 
dominant outcome in guinea pigs and rabbits (9). Fur-
thermore, L Ts were shown to produce renal vascular 
constriction in the anesthetized pig (24) but to produce 
dilation in the dog (4, 8). Thus conflicting results on 
hemodynamic effects of in vivo L Ts are also common. 
The rat is particularly useful for evaluating hemody-
namic effects of L Ts, since, in this species, the respira-
tory system is relatively resistant to the deleterious ef-
fects of LTs (10, 30). In the rat, LTs have been shown 
to increase systemic vascular resistance and vascular 
permeability and to lower cardiac output (CO; 1, 23, 29). 
L Ts were also shown to differentially affect various 
vascular beds in the rat (2, 29); for example, the mesen-
teric (M) artery was found to be more sensitive to L TD4 
administration than was the hindquarter (HQ) or renal 
(R) vessels (2). However, other sturlies in anesthetized 
rats (1) or in the isolated perfused rat kidney (25) dem-
onstrated greater renal constrictive potency for L Ts, 
whereas neither the M nor the R vascular beds were 
significantly effected in the pithed normotensive rat (29). 
These conflicting reports might be the result of different 
techniques of blood flow measurement, rat strain differ-
ences, anesthesia, or in vitro vs. in vivo conditions. No 
study to date has examined blood vessel responses to 
L Ts in the conscious rat. 
It is also pertinent to note that most of the L T effects 
described above were observed after bolus administra-
tion. However, continuous infusion of L Ts better simu-
lates sustained exposure of vascular tissue under patho-
physiological conditions, such as anaphylaxis. Moreover, 
the coronary arteries of the anesthetized domestic pig 
(7) show rapid tachyphylaxis to sustained infusion of 
L Ts, presumably due to release of platelet-dependent 
dilator factor (7, 10). Since rat platelets do not aggregate 
in response to these LTs (10), we postulated that the 
hemodynamic responses to sustained infusion of L Ts in 
the rat might be substantially different from the re-
sponses seen in the pig. Therefore, we also studied the 
effect of sustained L T infusion on both and regional 
hemodynamic responses of the conscious rat. 
Finally, the mechanism of the LT-induced vascular 
responses was studied by using the. potent cyclooxygen-
ase inhibitor, indomethacin (Indo), and two LT-receptor 
antagonists. The SRS-A and LT antagonist, FPL 55712, 
was shown toblock LTs' effects on several vascular and 
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nonvascular preparations, but several exceptions to this 
general property of FPL 55712 were reported as well as 
possible nonspecific effects on some vascular beds (9, 
25). A newer agent, LY 171883, is claimed to be an 
effective, long-acting LTs' antagonist (5, 11), but no data 
are available on its efficacy on specific blood vessels in 
vivo. 
Our study was designed, therefore, to further investi-
gate the systemic and regional hemodynamic effects of 
LTD4 and LTE4 administered in bolus or infusion to the 
conscious unrestrained rat. In addition, we evaluated the 
effects of pretreatment with the cyclooxygenase inhibitor 
Indo and with the LTs' antagonists, FPL 55712 and L Y-
171883, on the systemic and local vascular responses 
induced by L Ts. This study also emphasizes the potential 
role of L TE4 in hemodynamic modulation, since L TE4 
was poorly studied in the past while new information 
indicates that L TE4 might be the primary circulatory L T 
inshock and trauma (6). 
MATERIALSAND METHODS 
Male Sprague-Dawley rats (Taconic Farms, German-
town, NY) weighing 250-350 g were used in all sturlies 
(n = 26). Surgical procedures were performed under 
anesthesia with intramuscular solution of ketamine (130 
mg/kg) and acepromazine (1.3 mg/kg). Experiments were 
carried out on the conscious unrestrained rats, 1-3 days 
after operation. All rats were housed individually in 
standard plastic cages with food and water ad libitum. 
Regional blood flow measurements with directional 
pulsed Doppler technique. Miniaturized Doppler flow 
probes were implanted around the lower abdominal aorta 
for HQ blood flow measurement; the superior M and the 
left R arteries were also implanted with such probes by 
the method previously described by Haywood et al. ( 15). 
Briefly, a midline laparotomy was performed, and the 
superior M artery, the left R artery, and the lower aorta 
above its bifurcation were carefully isolated under a 
dissecting microscope. Miniaturized Doppler flow probes 
(Valpey-Fisher, Hopkinton, MA) were then loosely su-
tured (6-0 silk) around each vessel. The insulated wire 
leads of the probes were tunneled beneath the skin, 
exteriorized at the nape, and soldered to a receptacle 
which was then attached to the skull with small screws 
and dental acrylic. The femoral artery and vein were 
cannulated with polyethylene catheters (PE-50) which 
were also tunneled beneath the skin to exit at the nape. 
Catheters were regularly flushed (0.2 ml) with heparin-
ized saline (100 U/ml) and secured by a soft spring 
attached to the animal's neck with an adhesive collar. 
On the day of the experiment, the arterial line was 
connected to a pressure transducer (N arco Bio-Systems 
model RP 1500i) coupled to a strain gauge coupler (Narco 
Bio-Systems type 7179) and a biotachometer coupler 
(Narco Bio-Systems type 7032). Mean arterial blood 
pressure (MAP) and heart rate (HR) were continuously 
recorded on a N arcotrace 80 computerized dynograph 
and sampled (automatically or manually) at 15- to 60-s 
intervals by a Northstar-Hazeltine computer. A connec-
tor line was attached between the blood flow receptacle 
and a directional pulsed Doppler flowmeter (University 
of Iowa, Bioelectrical Engineering, Iowa). Outputsignals 
of Doppler shifts >4 kHz were simultaneously trans-
formed to mean flow velocity (KHz) and recorded con-
tinuously on the Narcotrace 80 through universal cou-
plers (type 7178). Local vascular resistance was calcu-
lated by dividing the MAP by the Doppler shift in KHz, 
as previously described (15). It is noteworthy that mea-
surements of MAP from the femoral artery cannula in 
the rat are virtually the same as the MAP in other 
arteries (e.g., brachial, mesenteric) in normal, hypoten-
sive, or hypertensive states (22). Changes in regional 
blood flow and local vascular resistance were further 
expressed as percent changes from control values. No 
differences in the basal signal level were found between 
the various experimental groups, since only signals of >4 
kHz for basallevels were considered appropriate. 
Experimental protocols. On the day of experiment, each 
animal was allowed to stabilize for at least 30 min while 
basal ( control) levels of the hemodynamic variables were 
recorded. Vehicle injections (0.9% NaCl, 300 ~1 iv) were 
used as controls for injection effects. To assess the con-
sistency of the various vascular responses, a bolus injec-
tion of norepinephrine (3 ~g/kg iv) was used; this test 
dose of norepinephrine caused a prompt increase in 
MAP, a decrease in HR, and a decreased blood flow in 
H Q, R, and M. After the stabilization period each animal 
was scheduled to one of the following protocols: 1) ad-
ministration of LTD4 or LTE4 (0.1, 1, 3, 10 }Lg/kg iv) as 
bolus injections in ascending order; 2) administration of 
LTD4 (10 ~g/kg iv) before and 1 min after treatment 
with the LT antagonist, FPL 55712 (10 mg/kg iv, given 
over 0.5-1 min); 3) administration of LTD4 or LTE4 (1 
and 10 ~g/kg iv) before and 15-60 min after treatment 
with the LT antagonist LY 171883 (30 mg/kg iv). This 
period (up to 60 min) was necessary to allow stabilization 
of cardiovascular parameters after L Y 171883 adminis-
tration, since this L T antagonist had definite intrinsic 
activity; 4) administration of LTD4 or LTE4 (3 ~g/kg iv) 
before and 30-60 min after treatment with Indo (5 mg/ 
kg iv). Each rat received only one LT to avoid any cross 
tachyphylaxis between the L Ts. 5) Continuous infusion 
of LTD4 (3 ~g·kg-1 ·min-1 ) over 10 min (27 ~1/min), 
using the Harvard Instruments, MA). 
LTD4 and LTE4 injections were separated by 15- to 
30-min intervals to allow for return to control values. 
The dose range chosen for administration of L Ts D4 and 
E4 and the intervals for complete recovery were based on 
previous reports from our laboratory (2). Doses of L Y 
171883 and FPL 55712 were based on previous in vivo 
sturlies which showed maximal antagonistic capacity for 
these agents in several preparations (1, 5, 11). 
Measurement of cardiac output. In eight additional 
rats, the effect of a continuous infusion of L TD4 on 
cardiac output and total peripheral resistance (TPR) was 
investigated. The rats were anesthetized with pentobar-
bitone ( 40 mg/kg ip), and PE-50 tu hing was inserted into 
the femoral arteries. These catheters were tunneled be-
neath the back skin and exited at the back of the neck 
as described above. Then an incision was made at the 
midline of the neck from the cricoid to the clavicle, and 
PE-50 tubing was inserted into the right atrium through 
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the external jugular vein. Then the left common carotid 
artery was exposed and ligated, and a thermistor (MX2-
780-33 model THMP f 1.5, Teflon reusable, Columbus 
Instruments, OH) was advanced through the carotid into 
the ascending aorta (placement above the aortic valve 
was confirmed in each animal at the end of the experi-
ment and by the shape of the dilution curve before the 
probe was finally sutured to the neck muscles). The 
jugular vein catheter and the thermistor were tunneled 
under the skin to the back of the neck. All lines were 
secured by a soft spring wire throughout the cage as 
earlier described. Twenty-four hours after surgery, the 
arterialline was connected to a blood pressure transducer 
for hemodynamic recordings. The cardiac output was 
measured by thermodilution technique as the thermistor 
was attached to the computerized Cardiomax II ( CMX2-
780-k with the microprobe option R, Columbus Instru-
ments, OH). The dead space of the venous line was first 
flushed with 0.05 ml of 0.9% (wt/vol) NaCl (saline) at 
room temperature (22°C); after abrief stabilization pe-
riod (10 s to ensure normal core temperature) an addi-
tional injection of0.2 ml normal saline (22°C) was rapidly 
injected using a 1-ml syringe. Cardiac output was re-
corded in the following way: a control period of 15 min 
included two to three cardiac output measurements to 
test for consistency and placement of the probe, and also 
to get control values for MAP and HR. Continuous 
infusion of LTD4 (3 !J.g· kg-1 • min-1) into the jugular vein 
(27 iJ.l/min) was done by means of the Harvard pump. 
The timer on the automatic data collection system was 
started at the beginning of the L TD4 infusion, and data 
points were taken at time (t) to, ta, ts, t10, tao min. TPR 
was calculated by dividing the MAP by the cardiac 
output; values of cardiac output and TPR were further 
indexed per unit of weight (kg). 
Drugs. Pure synthetic LTD4 and LTE4 (kindly pro-
vided by Dr. J. Rokach, Merck Frosst, Dorval, Canada) 
were aliquoted in distilled water and kept frozen ( -70oC) 
until used. Each aliquot was thawed only once and di-
luted with 0.9% NaCl to a final volume of 200-300 /oll for 
injection into the animal. FPL 55712 (kindly provided 
by Fisons Pharmaceuticals, Loughborough, UK) was dis-
solved in 0.45% saline solution at 40oC and further mixed 
with normal saline to a final concentration of 20 mg/ml. 
FPL 55712 was freshly prepared for each experiment. 
LY 171883 (kindly provided by Dr. J. Fleisch, Eli Lilly, 
Indianapolis, IN) was dissolved in 0.5 M sodium bicar-
bonate according to the manufacturer's directions and 
titrated to pH 8 with 0.1 M HCl. After being aliquoted it 
was kept frozen until use. Indo (Sigma, St. Louis, MO) 
was dissolved in 0.1 M sodium bicarbonate and titrated 
to pH 8.2 with 0.1 M HCl before use. Norepinephrine 
was also obtained from Sigma. 
Statistics. Data are presented in text and figures as 
means ± SE for the indicated number of rats. Analysis 
of variance (ANOV A) with repeated-measures, ANOV A 
followed by the Student-Newman-Keul test (SNK), or 
Dunnett's testwas used for statistical evaluation of the 
data. Where appropriate, a two-tailed paired Student's t 
test was also used. Differences were considered signifi-
cant when the P value was less than 0.05. 
RESULTS 
Effect of bolus injection of LTD4 and LTE4 on MAP 
and HR. The MAP and HR of the conscious rats prior 
to drug administration were 109 ± 2 mmHg and 377 ± 
13 beats/min, respectively. Control values did not differ 
between the various protocols. Systemic bolus adminis-
tration of increasing doses of LTD4 and LTE4 (0.1-10 
!J.g/kg iv) caused a dose-dependent increase in MAP (Fig. 
lA) that was maximal 30-60 s after injection and grad-
ually returned to controllevels (Fig. 1B). Lower doses of 
LTD4 and LTE4 (0.1 ~J.g/kg iv) did not affect MAP. 
Neither L TD4 nor L TE4 caused significant changes in 
HR. LTD4 was more potent than LTE4 in its pressor 
activity (Fig. 1, A and B). 
Effect of bolus injection of LTs D4 and E4 on regional 
blood flow and vascular resistance. Bolus administration 
of LTs D4 and E4 caused a differential response in the 
various vascular beds (Fig. 2). Both LTs D4 and E4 caused 
a dose-dependent reduction in M blood flow with con-
comitant increase in vascular resistance (Figs. 3 and 4). 
At the higher doses (10 J.Lg/kg iv) both LTD4 and L TE4 
caused a significant increase in R vascular resistance, 
but L TD4 showed a greater maximal potency and caused 
significant reduction of R blood flow at even lesser doses 
(Fig. 3). The HQ vascular bed showed a more complex 
response pattern to both LTD4 and LTE4. Within the 
1st min after injection, both L Ts caused an brief initial 
increase in HQ blood flow (HQ1), due to a decrease in 
vascular resistance (Figs. 2-5, HQ1 period). Shortly after 
the first phase of vasodilation, the HQ blood flow and 
vascular resistance showed an opposite response (reduc-
tion in blood flow and an increase in vascular resistance; 
HQ2). lt is important to point out that the secondary 
constrictor response (HQ2) became obvious only with 
higher doses (~3 !J.g/kg for L TD4 and 10 ~g/kg for LTE4), 
whereas lower doses produced only the initial dilator 
response (Figs. 3 and 4). Also, the HQ1 phasewas clearly 
seen at a dose of LTE4 (0.1 ~J.g/kg) which had no effect 
on MAP (Fig. 4). However, the HQl phase did not show 
a dose-response relationship within the range of doses 
used in this study. 
The initial dilator response occurred almost simulta-
neously with the opposite constrictor responses observed 
in the R and M vessels and with the developing pressor 
blood pressure response (Figs. 1, 2, and 5). At doses 
where MAP showed only minor or no changes (0.1-1 ~g/ 
kg) both LTD4 and LTE4 caused significant changes in 
blood flow and vascular resistance, mainly at the M 
vascular bed. Analysis of peak responses (ANOVA fol-
lowed by SNK) induced by L TD4 and L TE4 (Figs. 3 and 
4) showed differential sensitivity of the various vascular 
beds to their effects as follows: M >> HQ ~ R (P < 0.01; 
n =5-9). 
Effect of continuous infusion of LTD4 on MAP, regional 
blood flow, and vascular resistance. Continuous intrave-
nous infusion of LTD4 (3 J.Lg·kg-1 ·min-1) for 10 min 
caused gradual increases in MAP, HQ, R, and M vascular 
resistance. However, only M and HQ blood flow were 
significantly reduced (Fig. 6). The initial early dilator 
response (HQl) was no Ionger observed in the HQ ves-
sels. Analysis of peak responses revealed the same pat-
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FIG. 1. Effect of leukotrienes (LTs) D4 and E4 on blood pressure. A: maximal change in mean arterial pressure 
(ßMAP) to increasing doses of L TD, and L TE.. Asterisks denote significant differences between treatment and 
control groups (ANOVA followed by SNK). B: time course of pressor effect induced by LTD4 and LTE4 • ~MAP 
denotes change in mean arterial pressure from control levels. Asterisks denote significant differences between L TD4 
and LTE4 groups (ANOVA followed by SNK). F = 10.82; P < 0.001 (ANOVA with repeated measures). 
tern of differential sensitivity to L Ts for the various 
vascular beds, as follows: M >> HQ > R (P < 0.01; n = 
5). Discontinuation ofthe infusionwas followed by grad-
ual recovery of all the hemodynamic variables toward 
controllevels. However, even 20 min after the cessation 
of the infusion, M and HQ blood flow, and vascular 
resistance were still elevated, while MAP, R blood flow, 
and vascular resistance returned to base line. 
Effect of continuous infusion of LTD4 on cardiac output 
and TPR (Table 1). The base-line Ievels of MAP, HR, 
cardiac index, and TPR before intrajugular infusion of 
LTD4 (3 ~g-kg-1 -min-1 ) were 110 ± 4 (SE) mmHg, 422 
± 19 beats/min, 482 ± 21 ml·min-1 -kg-I, and 0.23 ± 
0.01 mmHg · ml-1 • min · kg, respectively. Infusion of LTD4 
over 10 min induced a sustained fall in cardiac index 
with a concomitant increase in TPR index. The maxi-
mum changes in cardiac and TPR indexes were reached 
5 min after the beginning of the infusion. Cardiac index 
remained low even 20 min after the end of the L TD 4 
infusion, whereas TPR index was significantly increased 
only during the 10 min of infusion. MAP transiently 
increased with a maximum of +10 ± 4 mmHg 3 min after 
the beginning of the L TD4 infusion. Also, LTD4 infusion 
induced a sustained tachycardia with a maximum in-
crease in HR of +86 ± 21 beats/min. 
Effect of pretreatment with Indo on the vascular re-
sponse induced by LTD4 and LTE4. Intravenous admin-
istration of Indo (5 mg/kg iv) 30-60 min before bolus 
injections of either LTD4 or LTE4 (3 ~g/kg iv) did not 
alter the LT -induced pressor or vascular responses (Ta-
ble 2). Indo did not effect base-line Ievels of MAP or 
regional blood flow at any of the monitored vascular beds 
(AMAP: -1 ± 1 mmHg, %.1 blood flow: -2 ± 3, +1 ± 3, 
+3 ± 3, for HQ, R, and M, respectively; n = 6, P > 0.05). 
Etfect of FPL 55712 and LY 171883 on the vascular 
response induced by LTD4 and LTE4• Intravenous admin-
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FIG. 2. Time course of the effect of 
leukotrienes (LTs) D4 and E4 on regional 
blood flow (A) and local vascular resist-
ance (B) expressed as %changes from 
controllevels (%8). Asterisks denote sig-
nificant differences between LTD4 and 
LTE4 groups (ANOV A followed by 
SNK). ANOV A with repeated measures 
revealed significant differences for hind-
quarter blood flow (F = 7.02; P < 0.001), 
hindquarter vascular resistance (F = 
5. 76, P < 0.001), and mesenteric vascular 
resistance (F = 2.60, P < 0.05) . 
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istration of FPL 55712 (10 mg/kg) produced a small but 
significant increases in MAP and HQ blood flow, without 
affecting HQ vascular resistance or R and M circulation 
(Table 3). FPL 55712 attenuated to the pressor response 
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FIG. 5. A typical simultaneous recording of arterial blood pressu.re 
(BP) and regional blood flow changes induced by leukotriene 0 4 (LTD.; 
1, 10 l'g/kg iv). Arrows represent injection time. 
and the increased vascular resistance induced by L TD 4 
but did not effect the dilator HQ response (HQ1) and 
had only a modest effect on the profound reduction in M 
blood flow (Fig. 7). 
LY 171883 (30 mg/kg iv) produced a significant in-
crease in blood flow with a concomitant decrease in HQ 
vascular resistance. L Y 171883 did not affect R or M 
circulation and did not change MAP (Table 3). L Y 
171883 effects on the vascular responses induced by 
LTD4 and LTE4 (1 or 10 J.Lg/kg iv) are summarized in 
Figs. 8 and 9, respectively. L Y 171883 attenuated the 
pressor response induced by L TD4 but not by LTE4• The 
HQ dilator response (HQ1) induced by the larger dose of 
LTD4 (10 J.Lg/kg) and the low dose ofLTE4 (1 J.Lg/kg) and 
the HQ constrictor response (HQ2) induced by the high 
dose of LTD4 (10 J.Lg/kg) were significantly attenuated 
by L Y 171883. Although L Y 171883 effectively blocked 
the M vascular response to L TD4 and L TE4, its effects 
on the profound drop in M blood flow were only minor, 
especially against the high doses of the L Ts. The changes 
in R blood flow and vascular resistance induced by LTD4 
(10 J.Lg/kg) were significantly blocked by LY 171883. The 
effect of L Y 171883 on the renal effects of L TE4 (1 and 
10 J.Lg/kg) and LTD4 (1 #Lg/kg) could not be evaluated, 
since no significant responses of the R vessels to these 
L Ts were obtained with these doses. 
DISCUSSION 
This study shows that LTs D4 and E4 induce differ-
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ences between treatment and control groups (ANOV A followed by 
SNK). Arrows with open squares represent onset of infusion. Solid lines 
indicate infusion period, and dashed lines indicate postinfusion period. 
HQ, hindquarters; R, renal; M, mesenteric. 
ential vascular effects in various blood vessels of the rat. 
The effects of LTD4 and LTE4 were qualitatively similar, 
but LTD4 was generally morepotent than LTE4 in all 
the vascular beds studied. The M artery was found to be 
most sensitive to the constrictor effect of the LTs, 
whereas the R artery was generally the least responsive 
vessel. U nlike previous studies, the present report 
showed that low doses of LTD4 and L TE4, which had no 
effect on MAP, caused significant increases in M vas-
cular resistance with concomitant decreases in M blood 
flow. Therefore, these changes can be considered direct 
ones and not a reflex response to systemic hemodynamic 
changes. However, larger doses of LTs invariably pro-
duced vascular constriction in all the areas studied and 
L TD4 was more potent then L TE4. 
These results generally confirm previous reports de-
scribing the constrictive vascular effects of L Ts in vivo 
(9). However, in the conscious state, all the vascular beds 
seem to be more sensitive to the constrictor effects of 
LTs, especially the R artery, which showed minimal or 
no response to LTD4 in the anesthetized or the pithed 
rat (2, 29). These differences might be related to the use 
of anesthetics, which were shown to effect L T responses 
(16) and the better physiological integrity of the con-
scious rat model. 
The results obtained by bolus injection of L Ts are 
further substantiated by data obtained through contin-
uous intravenous infusion of L TD4, a condition that 
might better reflect sustained release of L Ts during 
anaphylaxis or trauma situations. Infusion of LTD4 in-
duced a sustained pressor and differential vasoconstric-
tor response with the same potency order shown by bolus 
injections: M >> HQ > R. The TPR also markedly 
increased during L TD4 infusion, further indicating a 
potent systemic vasoconstrictor by sustained release of 
LTD4. It has recently been shown that antigen-induced 
anaphylaxis in conscious, sensitized rats can produce a 
similar pattern of circulatory changes. In the latter study, 
the M artery was the primary effected vessel, whereas R 
and HQ blood flow dropperl progressively only at later 
phases of the shock (31). 
In addition to the potent vasoconstriction, continuous 
infusion of LTD4 produced a marked long-lasting fall in 
cardiac index. Our results thus confirm earlier studies 
that LTD4 decreases cardiac output in anesthetized rats 
(1, 26, 29). However, the maximal fall in cardiac index 
was 29%, whereas TPR index increased almost 70%. 
Thus the changes in peripheral vascular resistance were 
much more pronounced than the fall in cardiac index. 
Interestingly, a profound tachycardic effect accompanied 
the LTD4-induced fall in cardiac index. Thus a decrease 
in cardiac contractility by LTD4, rather than a negative 
chronotropic effect on the heart, seems to account for 
the decreased cardiac index. Myocardial ischemia due to 
the well known coronary vasoconstrictor action by L TD4 
could explain the decreased contractility, but a direct 
myocardial depressor effect might also contribute (for 
review see Ref. 9). 
The special value of the conscious animal model is 
further demonstrated by the original finding of a dilator 
capacity for both L TD4 and L TE4 in the HQ vascular 
bed. The transient dilator phase in the HQ vascular bed 
TABLE 1. Effect of continuous intravenous infusion of LTD4 on cardiac output of the conscious rat 
~MAP,mmHg 
~HR, beats/min 
~Cl, ml·kg-1 ·min-1 
~TPRl, mmHg·ml-1 ·kg·min 
3 
+10±4* 
+65±19* 
-123±21t 
+0.11±0.02* 
Minutes after Start of LTD4 Infusion 
5 
+9±4 
+86±21t 
-139±28t 
+0.16±0.07t 
10 
+5±3 
+61±13* 
-135±16t 
+0.12±0.02* 
15 
-1±2 
±41±19 
-108±4t 
+0.07±0.01 
30 
-2±2 
+24±20 
-64±12* 
+0.04±0.02 
Values are means ±SE for 8 rats. Leukotriene D. (LTD.; 3 Jtg·kg-1 ·min-1) was infused over a 10-min period only. HR, heart rate; MAP, 
mean arterial pressure; Cl, cardiac index; TPRl, total peripheral resistance index. Statistical significance from basallevels (Dunnett's test) were 
determined as follows: * P < 0.05; t P < 0.01. 
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TABLE 2. Effect of pretreatment with Indo 
on changes in vascular resistance induced by 
LTD4 and LTE4 in conscious rat 
.!lMAP, % .!l Resistance 
n mmHg HQl HQ2 R M 
LTD,. 
Before Indo 4 +7±2 -15±3 +16±8 +5±5 +338±170 
After Indo 4 +10±3 -16±2 +12±5 +15±6 +293±82 
LTE,. 
Before Indo 6 +7±2 -6±3 +15±4 +7±4 +144±25 
After lndo 6 +8±3 -10±4 +27±12 +15±5 +106±15 
Values are means ± SE measured before and 30-60 min after 
administration ofindomethacin (lndo; 5 mg/kg iv). Changes in vascular 
resistance are expressed as %changes (%A) from base-line Ievels for 
each group. AMAP presents change in mean arterial pressure. Paired 
Student's t test for groups before and after Indo did not reveal signifi-
cant differences. n = no. of rats in each group. HQ1 and HQ2, hind-
quarter dilator and constrictor responses, respectively; R and M, renal 
and mesenteric arterial flow, respectively. Leukotrienes (LTs) D. and 
E4 were administered at 3 J.Lg/kg iv. 
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FIG. 7. Effect of FPL 55712 (10 mg/kg iv) on the vascular response 
induced by leukotriene D4 (LTD.; 10 J.Lg/kg iv). Asterisks denote signif-
icant differences between groups before and after pretreatment calcu-
lated for %changes from controllevels (two-tailed paired Student's t 
test). Blood flow and vascular resistance are expressed as %changes 
from controllevels (%A). 
preceded the more sustained constrictor phase and was 
more apparent at low doses of L Ts, which had only 
minor constrictor activity. This dilator phasewas rapidly 
overridden by the potent constrictor effect of higher 
doses of LTs. Since the HQ vascular bed consists pri-
marily of skeletal musdes it is conceivable that this 
dilator phase originates in the skeletal muscle vessels. 
Previous sturlies demonstrated the dilator capacity of 
L TD4 in the canine renal artery, the hypoxic ductus 
arteriosus of the fetal lamb, and the human skin (9). 
These studies, however, did not demonstrate the dual 
capacity for L Ts to induce opposite responses in the 
same vascular bed. A recent study showed a very similar 
pattern of hindquarter and carotid blood flow changes in 
the anesthetized pig, but only for LTC4 and not for LTD4 
(13). In the latter study, vascular resistance was not 
evaluated, and increased blood flow could have been 
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merely the result of increased MAP. Species differences 
may also account for the observed differences (9). The 
dilator response presented in this study may best be 
correlated with the single report of the effect of L TC4 on 
human vasculature in vivo ( 17). In humans, L TC4 dilates 
the pulmonary and brachial arteries and increases blood 
flow; no vasoconstriction was observed. 
L Ts were previously shown to release cyclooxygenase 
products from various tissues which in turn mediate part 
of their action in some vascular preparations (9). In the 
present study, Indo did not effect the dilator or the 
constrictor properties of L TD4 or L TE4 in the conscious 
rat. This finding generally confirms previous sturlies in 
the rat species (1, 25, 30), but furthermore, it suggests 
that not only systemic but regional hemodynamic re-
sponses to L Ts as well are probably not mediated by 
cyclooxygenase metabolites of arachidonic acid. In other 
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TABLE 3. Effect of FPL 55712 and LY 171883 on MAP, regional blood flow, and uascular resistance in conscious rat 
.1MAP, 
mmHg 
%.1 Blood Flow %.1 Resistance 
HQ R M HQ R M 
FPL 55712 (n =5-7) +8±3* +17±6* +6±3 +4±6 -6±6 +4±5 +10±8 
L Y 171883 (n = 6-7) +2±2 +24±2t -6±6 +7±4 -19±2* +9±8 -4±4 
Values are means ± SE measured 1 and 15 min after intravenous administration of FPL 55712 (10 mgfkg) and LY 171883 (30 mg/kg), 
respectively. ~MAP represents change in mean arterial pressure. Changes in blood flow vascular resistance are expressed as %changes from 
controllevels (%~). n, no. of rats in each group. HQ, hindquarter; R, renal artery; M, mesenteric artery. * and t denote P < 0.05 and P < 0.01, 
respectively for differences from controllevels (ANOVA followed by SNK). 
species (e.g., the domestic pig), LTD4 was shown to 
produce a vasodilator response in vivo that was mediated 
by a platelet-dependent factor which was not an arachi-
donate metabolite (7, 20). Moreover, recent sturlies 
showed endothelium-dependent relaxing capacity for 
LTD4 on precontracted blood vessels (28). Again, the 
relaxing activity of L Ts in such preparations were inde-
pendent of arachidonate metabolites. Thus it is possible 
that the dilator effect of LTs D4 and E4 on HQ vessels 
in our study might be mediated by a still unknown dilator 
factor derived from blood-borne or endothelial cells. 
It was previously suggested that several L T receptors 
mediate the various effects of L Ts on various cells and 
organs (12). It was also suggested that vascular receptors 
to L Ts are differentially distributed in various vascular 
beds (2, 4, 8, 25, 29). The similar pattern of the vasocon-
strictor response induced by L TD 4 and L TE4 in our study 
may suggest activation of one type of vascular receptor 
to LTD4. The somewhat greater potency of LTD4 vs. 
LTE4 suggests that this receptor is primarily a LTD4 
receptor. This is in accord with most of the previous 
studies that showed greater potency for L TD4 vs. L TE4 
(3, 4, 8, 25). However, the initial dilator response at the 
HQ vascular bed of the conscious rat was the same for 
both LTD4 and LTE4 and suggests the existence of yet 
another type of a vascular receptor for these L Ts. How-
ever, it should be pointed out that the dilator response 
to LTs in the HQ was not dose dependent, probably 
owing to the rapid onset of the constrictor phase (HQ2) 
at somewhat higher doses. This suggestion is supported 
by the demonstration that FPL 55712 did not effect this 
dilator response, though it significantly attenuated the 
constrictor responses. 
The recently developed L T antagonist L Y 171883 pro-
duced vasodilation in the HQ vascular bed. Therefore, 
its antagonistic action on both the dilator and constrictor 
responses induced by L TD4 and L TE4 in the HQ may be 
not entirely specific. Nevertheless, without affecting 
other vascular beds or MAP, L Y 171883, in a relatively 
high dose, attenuated the pressor response induced by 
LTD4 but not by LTE4; the constrictor effects of both 
L Ts on the M artery was also significantly suppressed. 
This may further support the suggestion that one type 
of L T receptor mediates their constrictor response and 
is in accord with previous sturlies that suggest activation 
of one receptor site for LTD4 and LTE4 (21) and showed 
the capacity of LY 171883 to antagonize both (11). 
However, it may also suggest that the pressor response 
induced by L TE4 in the conscious rat is mediated by a 
different receptor from LTD4. Moreover, if the attenua-
tion of the HQ dilator response by L Y 171883 for LTE4 
is rather specific, one could argue that the pressor, dila-
tor, and constrictor effects of L TE4 are all mediated by 
different receptors. Clarification of these possibilities 
awaits for more selective L T ,antagonists. 
N-acetyl-LTE4 has recently been found tobe the pre-
dominant endogenous plasnia metabolite of L Ts after 
various trauma in the anesthetized rat (6). In the con-
scious rat, L TE4 was equipotent to L TD4 to cause a 
profound drop in M blood flow. Thus the metabolic 
process that converts L TC4 to L TD4 to L TE4 in vivo 
(27) does not result in effective reduction of their overall 
deleterious hemodynamic potency. Therefore, L TE4 
might also have a role in the pathophysiological situa-
tions where L Ts are released. The limited capacity of 
both FPL 55172 and LY 171883 to protect the mesenter-
ium from the sustained ischemia by L Ts in the conscious 
rat should encourage an active search for better L T 
antagonists. 
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